[79] Prieto-González S,

García-Martínez A, Tavera-Bahillo I, et al. Effect of glucocorticoid treatment on computed tomography angiography detected large-vessel inflammation in giant-cell arteritis. A prospective, longitudinal study. Medicine. 2015; 94(5):e486.

[80] Prieto-González S, Arguis P, Cid MC. Imaging in systemic vasculitis. Curr Opin Rheumatol. 2015; 27:53-62.

[81] Klink T, Geiger J, Both M, et al. Giant cell arteritis: Diagnostic accuracy of mr imaging of superficial cranial arteries in initial diagnosis-results from a multicenter trial. Radiology 2014;273(3):844-582.

[82] Quinn KA, Ahlman MA, Malayeri AA, et al. Comparison of magnetic resonance angiography and 18 F-fluorodeoxyglucose positron emission tomography in large-vessel vasculitis. Ann Rheum Dis. 2018; 77(8):1166-1172.

[83] Lariviere D, Benali K, Coustet B, et al. Positron emission tomography and computed tomography angiography for *Extra-Cranial Involvement in Giant Cell Arteritis DOI: http://dx.doi.org/10.5772/intechopen.97715*

the diagnosis of giant cell arteritis: A real-life prospective study. Medicine. 2016; 96(30):e4146.

[84] Soussan M, Nicolas P, Schramm C, et al. Management of large-vessel vasculitis: a systematic literature reviwe and meta-analysis with FDG-PET. Medicine. 2015; 94(14):e622

[85] Nielsen BD, Gormsen LC, Hansen IT, et al. Three days of high-dose glucocorticoid treatment attenuates large-vessel 18F-FDG uptake in largevessel giant cell arteritis but with a limited impact on diagnostic accuracy. Eur J Nucl Med Mol Imaging. 2018; 45(7):1119-1128.

[86] Hellmich B, Agueda A, Monti S, et al. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2020;79(1):19-30.

[87] Hoffman GS, Cid MC, Hellmann DB, et al. A multicenter, randomized, double-blind, placebocontrolled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum. 2002;46(5):1309-1318.

[88] Jover JA, Hernández-García C, Morado IC, et al. Combined treatment of giant-cell arteritis with methotrexate and prednisone: A randomized, doubleblind, placebo-controlled trial. Ann Intern Med. 2001;134(2):106-114.

[89] Hoffman GS, Cid MC, Rendt-Zagar KE, et al. Infliximab for maintenance of glucocorticosteroidinduced remission of giant cell arteritis a randomized trial. Ann Intern Med. 2007;146(9):621-630.

[90] Martínez-Taboada VM, Rodríguez-Valverde V, Carreño L, et al. A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Ann Rheum Dis. 2008;67(5):625-630.

[91] Seror R, Baron G, Hachulla E, et al. Adalimumab for steroid sparing in patients with giant-cell arteritis: Results of a multicentre randomised controlled trial. Ann Rheum Dis. 2014;73(12):2074-2081.

[92] Stone JH, Tuckwell K, Dimonaco S, et al. Trial of Tocilizumab in Giant-Cell Arteritis. N Engl J Med. 2017;377(4): 317-328.

[93] Calderón-Goercke M, Castañeda S, Aldasoro V, et al. Tocilizumab in giant cell arteritis: differences between the GiACTA trial and a multicentre series of patients from the clinical practice. Clin Exp Rheumatol. 2020;38(2):112-119.

[94] Camellino, D; Morbelli S, Sambuceti GCM. Methotrexate treatment of polymyalgia rheumatica/ giant cell arteritis associated large vessel vasculitis. Clin Exp Rheumatol. 2010;28:288-289.

[95] Muratore F, Bolardi L, Restuccia G, et al. Relapses and long-term remission in large vessel giant cell arteritis in northern Italy: Characteristics and predictors in a long-term follow-up study. Sem Arthritis Rheum. 2020; 50(4):549-558.

[96] Tuckwell K, Collinson N, Klearman M, et al. FRI0377 Classification Criteria for Giant Cell Arteritis: Data from Giacta Informing The Need for Revision. Ann Rheum Dis 2016;75**:**571.

[97] Leuchten N, Aringer M. Tocilizumab in the treatment of giant cell arteritis. Immunotherapy. 2018;10(6):465-472.

[98] Conway R, O'Neill L, O'Flynn E, et al. Ustekinumab for the treatment of refractory giant cell arteritis. Ann Rheum Dis. 2016; 75:1578-1579.

[99] Matza MA, Fernandes AD, Stone JH, Unizony SH. Ustekinumab for the Treatment of Giant Cell Arteritis. Arthritis Care Res. 2020; doi: 10.1002/ acr.24378.

[100] Langford CA, Cuthbertson D, Ytterberg SR, et al. A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Giant Cell Arteritis. Arthritis Rheumatol. 2017; 69(4):837-845.

[101] Cid M, Unizony S, Pupim L, et al. Mavrilimumab (anti GM-CSF Receptor α Monoclonal Antibody) Reduces Time to Flare and Increases Sustained Remission in a Phase 2 Trial of Patients with Giant Cell Arteritis. Arthritis Rheumatol. 2020;72(Suppl 10).

[102] Baricitinib in Relapsing Giant Cell Arteritis C.incialTrials.gov: clinicaltrials.gov/ct2/show/ NCT03026504

[103] A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis. ClinicalTrials. gov:clinicaltrials.gov/ct2/show/ NCT03725202

[104] Kermani TA, Warrington KJ, Crowson CS, et al. Large-vessel involvement in giant cell arteritis: A population-based cohort study of the incidence-trends and prognosis. Ann Rheum Dis. 2013;72(12):1989-1994.

[105] García-Martínez A, Arguis P, et al. Prospective long term follow-up of a cohort of patients with giant cell arteritis screened for Aortic structural damage (aneurysm or dilatation). Ann Rheum Dis. 2014;73(10):1826-1832.

[106] Gonzalez-Gay MA, Garcia-Porrua C, et al. Aortic aneurysm and dissection in patients with biopsyproven giant cell arteritis from northwestern Spain: A population-based study. Medicine. 2004;83(6):335-341.

[107] Blockmans D, Coudyzer W, Vanderschueren S, et al. Relationship between fluorodeoxyglucose uptake in the large vessels and late aortic diameter in giant cell arteritis. Rheumatology. 2008;47(8):1179-1184.

[108] De Boysson H, Liozon E, Lambert M, Parienti JJ, Artigues N, Geffray L, et al. 18 F-fluorodeoxyglucose positron emission tomography and the risk of subsequent aortic complications in giant-cell arteritis. Medicine. 2016;95(26):e3851.

[109] Matteson EL, Gold KN, Bloch DA, Hunder GG. Long-term survival of patients with giant cell arteritis in the American College of Rheumatology giant cell arteritis classification criteria cohort. Am J Med. 1996;100(2):193-196.

[110] Proven A, Gabriel SE, Orces C, et al. Glucocorticoid Therapy in Giant Cell Arteritis: Duration and Adverse Outcomes. Arthritis Care Res. 2003;49(5):703-708.
